Gossamer Bio Inc(GOSS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:23 PM ET (Korea 9/12 06:23)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -55.66 | Insider Own | 8.28% | Shs Outstand | 6.1M | Perf Week | -23.62% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 30.47% | Insider Trans | - | Shs Float | 5.6M | Perf Month | -24.48% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -3.69 | Inst Own | 72.57% | Short Float | 18.43% | Perf Quarter | -24.39% |
| Income | -0.13B | P/S | 1.23 | EPS this Y | 70.25% | Inst Trans | 10.43% | Short Ratio | 3.02 | Perf Half Y | -70.84% |
| Sales | 0.05B | P/B | - | EPS next 5Y | 46.48% | ROA | -78.81% | Short Interest | 1.03M | Perf YTD | -95.67% |
| Book/sh | -15.39 | P/C | 1.15 | EPS past 3/5Y | 34.98% 26.82% | ROE | -783.37% | 52W High | -96.53% ($309.60) | Perf Year | -96.12% |
| Cash/sh | 9.33 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 17.86% ($9.10) | Perf 3Y | -86.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 7.4% | Gross Margin | 98.25% | Volatility(W/M) | 10.29% 11.64% | Perf 5Y | -98.67% |
| Dividend TTM | - | EV/Sales | 0.91 | Sales Y/Y TTM | 32.43% | Oper. Margin | -297.67% | ATR (14) | 1.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.53 | EPS Q/Q | 54.51% | Profit Margin | -235% | RSI (14) | 36.66 | Recom | 2.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.53 | Sales Q/Q | -19.59% | SMA20 | -18.14% ($13.11) | Beta | 2.21 | Target Price | $132.8 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -20.12% ($13.43) | Rel Volume | 1.39 | Prev Close | $11.39 |
| Employees | 162 | LT Debt/Eq | - | EPS/Sales Surpr. | 35.19% 154.57% | SMA200 | -87.2% ($83.83) | Avg Volume(3M) | 0.34M | Price | $10.73 |
| IPO | 2019/2/8 | Option/Short | Yes/Yes | Trades | 6243 | Volume | 473,256 | Change | -5.81% |
Company
고사머 바이오GOSS | NASD | Biotechnology GOSS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🫁 This is a US biopharmaceutical company that focuses on pulmonary arterial hypertension as its core disease area and is developing an inhaled therapeutic candidate called seralutinib. Based in California, the company initially maintained a broad pipeline spanning oncology and inflammation but has since narrowed its strategy to concentrate resources on a single lead asset. As a clinical-stage company, partnerships and the management of development funding form the core of its business rather than product sales.
Over the past 1 year, on the lower side
97% below its 1-year high.
GOSS has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +70.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -86.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 72.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBC 0.00%
IWC 0.00%
PRFZ 0.00%
ESSC 0.00%
GSSC 0.00%It ranks #4 in the industry
Based on market cap of $66M.
GOSS $66M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is GOSS?
GOSS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GOSS?
The market cap of GOSS is approximately $66M, ranking 4,818 within its sector.
What is the 52-week high and low for GOSS?
GOSS has recorded a 52-week high of $309.60 and a low of $9.10.
